Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa-Reference-Cited by-同舟云学术

Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa

Published:2024-01 Issue: Volume:233 Page:135-137
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Megías-Vericat J.E.^ORCID,Bonanad Boix S.^ORCID,Cid Haro A.R.,Haya Guaita S.^ORCID,Aguilar-Rodríguez M.^ORCID,Marqués-Miñana M.R.,Bosch P.,Poveda Andrés J.L.

Funder

Swedish Orphan Biovitrum

Publisher

Elsevier BV

Subject

Hematology

Reference10 articles.

1. Defining extended half-life rFVIII-A critical review of the evidence;Mahlangu;Haemophilia,2018

2. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B;Wang;Haemophilia,2018

3. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors’ Organisation;Brennan;Haemophilia,2020

4. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: lessons learned with the CHO-KLAT tool;Carcao;Haemophilia,2020

5. Optimising prophylaxis outcomes and costs in Haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience;Tagliaferri;Blood Transfus.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project;Pharmaceuticals;2024-06-25